Mr. Adel shares his journey of living with prostate cancer and receiving Lutetium-177-PSMA Radioligand Therapy. As one of the first patients supported through the RLT-Connect dose donation program, his story reflects both the challenges of facing diagnosis, chemotherapy, and hormone therapy, and the renewed hope that radioligand therapy has brought to his life.
More than a medical treatment, Mr. Adel’s experience is a reminder of the strength of patients, the importance of access, and the possibilities of innovative cancer care.
